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LysosomesLysosomes were discovered by Chistian de Duve in 1955 more or
less by serendipity. De Duve was primarily interested in elucidating
the hepatic actions of insulin. He had prepared subcellular fractions
enriched in acid phosphatase and noticed that the activity in this
fraction reproducibly increased after it was left in the refrigerator for
some days. He considered this phenomenon as sufﬁciently odd to
investigate its molecular basis. His curiosity led to the insight that the
enzyme was present within membrane limited particles which
ruptured and released the enzyme after aging in the refrigerator.
Christian de Duve succeeded to separate these particles from
mitochondria and microsomes and he realized that they contain
besides acid phosphatase several other hydrolases. This led him to
suggest that these newly discovered particles constitute a degradative
compartment of general function. Therefore he termed these particles
lysosomes. This discovery earned him the Nobel Prize in 1974.
At the time of this discovery, the MD Gery Hers worked with De
Duve. Hers was interested in disorders of metabolism such as
glycogen storage diseases. He noticed that, in one of the glycogen
storage disease – Pompe disease – an acid glucosidase was deﬁcient.
Because of his tight connections to De Duve, he immediately realized
that this hydrolase must be lysosomal. This led him to consider
Pompe diseases a lysosomal disease and he suggested the more
general concept of inborn lysosomal diseases. This led to a rapid
extension of the ﬁeld and within a few years after Hers publication
many lysosomal hydrolases were identiﬁed and other disorders were
classiﬁed as lysosomal storage diseases. By 1980, receptor-mediated
endocytosis was recognized to be of central importance for the
lysosomal pathway. Experiments performed by Elizabeth Neufeld
with ﬁbroblasts of patients suffering from mucopolysaccharidosis set
the stage for the identiﬁcation of mannose-6-phosphate as an
important posttranslational modiﬁcation for delivery of soluble
lysosomal enzymes to lysosomes and the identiﬁcation of mannose-
6-phosphate receptors as essential components for lysosomal sorting.
At the same time, these experiments also provided the rationale for
enzyme replacement therapies, which since then have been clinically
established for some of the lysosomal storage diseases. Cloning of
genes of lysosomal proteins dominated research in the 1990s. Many
genes of lysosomal enzymes were cloned and characterized and
mutations causing the respective diseases were identiﬁed. Molecular
biology led to the identiﬁcation of sorting and transport signals in
lysosomal membrane proteins and a better understanding of the
mechanisms of endocytic sorting and delivery of compounds to the
lysosome was achieved.
Already in the 1970s, Roscoe Brady had promoted the concept of
enzyme replacement therapy in lysosomal storage diseases, which
ﬁnally led to the clinical application in Gaucher disease in which this
therapeutic approach is highly successful. The success of enzyme0167-4889/$ – see front matter © 2009 Published by Elsevier B.V.
doi:10.1016/j.bbamcr.2009.03.001replacement in Gaucher disease was the basis for the extension of this
approach to other lysosomal diseases. This prompted the industrial
production of lysosomal enzymes for clinical application in various
lysosomal disorders. Besides this protein-based treatment, small
molecule-based therapies are also under development. This include
substrate reduction therapies in which the synthesis of the
accumulating compound is inhibited and molecular chaperone
therapies in which the delivery of mutant lysosomal enzymes to
lysosomes is improved. The availability of mouse models for many
diseases enabled research on experimental therapies such as gene
therapy or stem cell-based therapies. Whereas for a few diseases gene
therapy is in the late preclinical stages and trials in humans will be
performed soon, currently the ﬁrst patients with tripeptidyl pepti-
dase I-deﬁciency underwent the ﬁrst AAV-mediated therapeutic trial.
The following review series updates on several aspects of
lysosomal biology mentioned in this brief historical overview. Thus,
in the last years, many details of the cellular routes delivering
compounds to lysosomes have been revealed. The sorting of resident
soluble and transmembrane lysosomal proteins from the biosynthetic
route or the plasma membrane to the lysosomes is the focus of the
contribution of T. Braulke and J.S. Bonifacino. Endocytosis is one of the
major routes delivering proteins, lipids, and other compounds for
lysosomal degradation. Advances in our understanding of this route
with particular emphasis on proteins are reviewed by P.R. Pryor and
J. P. Luzio. Autophagy is essential to cells and provides a pathway by
which intracellular material is delivered to the lysosome. The
importance of this pathway is highlighted by the contribution of
E.-L. Eskelinen and P. Saftig. Taking lipids as an example, the
contribution of H. Schulze, T. Kolter, and K. Sandhoff reviews how
degradation of compounds occurs after delivery to the lysosome.
Much has been learned from studies on the vacuole as the
lysosomal equivalent of yeast. As for other cellular processes, the
power of generating yeast mutants has led to the identiﬁcation of
important cellular players in lysosomal biology as summarized by S.C.
Li and P.M. Kane. Proteomics has been proven to identify as yet
unknown mannose 6-phosphate-containing lysosomal proteins and
has been applied selectively to the lysosomal membrane. Several
interesting proteins, which were newly recognized through this
methodology, are in the focus of the contribution of T. Lübke, P. Lobel,
and D.E. Sleat. In contrast to the “classical” soluble lysosomal
hydrolases, the knowledge about the function of lysosomal membrane
proteins is lagging somewhat behind but has made considerable
progress in recent years as outlined in the contribution of B. Gasnier
and colleagues. Research on lysosomal function has always been
fueled by the existence of more than 50 different genetically and
clinically deﬁned lysosomal storage diseases. Our understanding of
how storage material actually elicits its detrimental effects and its
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604 Prefacecontribution to the pathogenesis of these disorders is only in its early
stages and will be a major research area in the next years. A number of
processes, such as the cellular effects of storage material, however,
have already been identiﬁed and are reviewed by A. Ballabio and V.
Gieselmann. In addition, secondary accumulation of non-degraded
material may contribute to the pathogenesis of lysosomal storage
diseases and is reviewed by S.U. Walkley and M.T. Vanier. Neuronal
Ceroid Lipofuscinoses comprise a group of diseases, which are
genetically heterogeneous but share common clinical features. These
disorders are themost frequent cause of neurodegeneration in children.
The lysosomal implications in these diseases have only been
appreciated in recent years as reviewed by A. Jalanko and T. Braulke.
For the non-expert, it is frequently surprising that lysosomal storage
can also be due to the deﬁciency of proteins, which are not primarily
lysosomal. These defects are covered in the review of T. Dierks and
coauthors. Lysosomes do play a pathogenic role not only in the
respective storage disorders, but also inmore frequent diseases. As an
example, T. Kierkegaard and M. Jaattela review the function of
lysosomes in cancer.
About 20-30 years ago, lysosomal storage diseases have been
considered as untreatable. This has changed considerably in particular
in the last decade. For some diseases, treatment is now clinically
established. Many other therapeutic approaches are either in the early
experimental stages, preclinical development or in already in clinical
trials. The available therapeutic options are discussed in the contribu-
tion of F.M. Platt and R.H. Lachmann.
This issue of BBA Molecular Cell Research highlights advances in
lysosomal research in recent years. The expanding area of research on
lysosomes makes it difﬁcult to cover every aspect with a limited
number of reviews. Thus, reviews on lysosome-related organelles and
on the role of lysosomes in infectious diseases for example were
exempted because they have been covered by various excellent
reviews published just recently.
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